Ask AI
Back Back1

MISSION POSSIBLE: Are We Doing Enough to Prevent Acute Pancreatitis in Severe Hypertriglyceridemia?

Start Activity
Clinical Thought
Clinical Thought Start Activity
See Activity Information

Released: October 30, 2026

See Activity Collection

Step 1 of 2

1 ClinicalThought 2 Complete Activity

Severe hypertriglyceridemia (sHTG) is a clinically significant yet frequently underrecognized disorder encountered in cardiovascular practice, associated with an increased risk of acute pancreatitis and potentially serious complications. Timely risk recognition, appropriate treatment selection, and effective triglyceride lowering are essential to reducing this risk. This ClinicalThought commentary explores practical strategies for risk assessment, optimizing treatment decisions, and incorporating emerging therapies into clinical practice to improve outcomes for patients with sHTG.

Zahid Ahmad
Zahid Ahmad, MD, FNLA
Acute Pancreatitis in Severe Hypertriglyceridemia

Continue

For cardiologists, triglycerides are often considered primarily through the lens of cardiovascular risk. But when triglyceride levels become severely elevated, another question becomes increasingly important: Are we doing enough to prevent acute pancreatitis? 

Clinical Burden
Severe hypertriglyceridemia (sHTG), generally defined as triglycerides ≥500 mg/dL, is a common problem. US population data have suggested that approximately 1.7% of adults have triglycerides at or above this level, and as triglycerides rise, the clinical stakes change. At ≥500 mg/dL, pancreatitis prevention becomes an important treatment consideration; at ≥1000 mg/dL, it becomes an increasingly urgent concern. That shift matters because the way we think about triglycerides in patients with mild or moderate hypertriglyceridemia is not necessarily the way we should think about a patient whose triglycerides are 800, 1500, or 3000 mg/dL. In the former, our focus may largely be long-term atherosclerotic cardiovascular disease risk. In the latter, we also have to confront a potentially serious short-term complication: acute pancreatitis.

This raises a practical question: When triglycerides become severely elevated, do we sufficiently shift our clinical focus from simply managing cardiovascular risk to actively preventing pancreatitis? 

Diagnostic Challenges
When a patient presents with a very high triglyceride level, the first question is often the most important: Why are the triglycerides this high? 

For most patients, sHTG is multifactorial rather than the result of a single rare genetic disorder. An underlying susceptibility may be amplified by common secondary factors such as poorly controlled diabetes, excess adiposity, alcohol use, dietary factors, kidney or endocrine disease, or medications. These contributors can accumulate. A patient whose triglycerides were previously moderately elevated can develop severe or even extreme hypertriglyceridemia when several metabolic or environmental factors converge. That makes a search for reversible causes fundamental. Is diabetes adequately controlled? Has alcohol intake changed? Has the patient gained weight? Is there substantial intake of refined carbohydrates or dietary fat? Has a new medication been started? Could hypothyroidism, renal disease, pregnancy, or another medical condition be contributing? Sometimes the most effective intervention begins not with adding another triglyceride-lowering drug, but with identifying and correcting the factor that pushed a susceptible patient into a much higher-risk range. 

But secondary causes are not the entire story. Are the triglycerides intermittently severe, or are they persistently extreme? Did the problem begin early in life? Has the patient experienced recurrent abdominal pain or pancreatitis? Have conventional therapies produced the response we would expect? 

Persistent, extreme hypertriglyceridemia, particularly when accompanied by early onset, recurrent pancreatitis, and limited response to conventional treatment, should raise the possibility of an underlying genetic chylomicronemia syndrome. Familial chylomicronemia syndrome is rare, but recognizing it is important because its biology, clinical course, and response to therapy differ from the far more common multifactorial forms of severe hypertriglyceridemia. The diagnostic challenge is therefore not simply to label a triglyceride level as “high,” but to determine what phenotype is in front of us and what is driving that patient’s pancreatitis risk. 

Treatment Challenges
Once we identify the risk, the next question is: How aggressively should we treat it? 

Lifestyle intervention and correction of secondary factors remain foundational. When triglycerides are very high, dietary fat restriction can become particularly important, together with avoidance of alcohol, attention to refined carbohydrates, weight management when appropriate, and aggressive treatment of uncontrolled diabetes or other contributing conditions. Yet implementing these changes can be difficult, particularly when the degree of dietary restriction required is substantial. 

Pharmacologic treatment presents another challenge. Fibrates and prescription omega-3 fatty acids have long been part of the treatment approach for severe hypertriglyceridemia. But how should we decide when those approaches are sufficient? What should we do when triglycerides remain markedly elevated despite addressing secondary causes and using conventional therapy? And should our treatment decisions be based on the triglyceride number alone, or should a patient's prior pancreatitis history, persistence of chylomicronemia, and underlying phenotype influence how aggressively we intervene?

These questions have become even more relevant as therapies directed at apolipoprotein C-III have changed the treatment landscape. Recent trials demonstrate that substantial triglyceride lowering can be achieved in patients with chylomicronemia and sHTG, with emerging evidence that treatment can also reduce pancreatitis events. This moves the conversation beyond simply asking, “How much can we lower triglycerides?” toward the more clinically meaningful question: Can we prevent pancreatitis in the patients who are most likely to experience it? 

That distinction is important. A triglyceride value is a biomarker. Acute pancreatitis is the outcome that can bring a patient to the emergency department or hospital and can recur in patients who remain at risk. The objective of treatment in sHTG is therefore not simply to make the laboratory report look better. It is to recognize risk, identify and reverse the causes we can, and use available therapies appropriately to prevent clinically meaningful events. 

As we prepare for the upcoming in-person satellite symposium “MISSION POSSIBLE: Elevating Risk Recognition, Treatment Decisions, and Pancreatitis Prevention in Severe Hypertriglyceridemia” on November 8, 2026, in Chicago, Illinois, I would encourage healthcare professionals to consider a few questions about their own practice: When you encounter triglycerides ≥500 mg/dL, does your clinical thinking change? How systematically do you look for secondary causes? How do you identify patients whose persistent or extreme hypertriglyceridemia may represent an underlying chylomicronemia syndrome? When conventional approaches are insufficient, how do you decide to escalate therapy? And, of most importance, how confident are you that you can identify the patients at greatest risk of pancreatitis and choose the strategy most likely to reduce that risk? 

These are the practical questions we will explore during the live program. Severe hypertriglyceridemia is no longer just a number to recognize. It is a clinical problem that asks us to connect the triglyceride level to its cause, the patient's phenotype, and the outcome we are ultimately trying to prevent: acute pancreatitis. 

Your Thoughts
How confident are you in identifying patients at risk of acute pancreatitis in sHTG? You can get involved in the conversation by answering the poll question and posting a comment below. You can register for the upcoming satellite symposium here.

Continue

Poll

1.

How confident are you in identifying patients at risk of acute pancreatitis in sHTG?

Submit